Cargando…
Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours.
Sera from C57Bl/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich (allogeneic) and RL male 1 (syngeneic) ascites tumours in BALB/c mice. Sera obtained from mice 24 h after Ge-132 administration displayed the greatest antitumour effect and this was dose dependent. Sera p...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977232/ https://www.ncbi.nlm.nih.gov/pubmed/3933536 |
_version_ | 1782135218036015104 |
---|---|
author | Suzuki, F. Brutkiewicz, R. R. Pollard, R. B. |
author_facet | Suzuki, F. Brutkiewicz, R. R. Pollard, R. B. |
author_sort | Suzuki, F. |
collection | PubMed |
description | Sera from C57Bl/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich (allogeneic) and RL male 1 (syngeneic) ascites tumours in BALB/c mice. Sera obtained from mice 24 h after Ge-132 administration displayed the greatest antitumour effect and this was dose dependent. Sera prepared from mice 12, 36, or 48 h after Ge-132 treatment had no protective effect. Circulating interferon (IFN) was induced at 24 h after administration of Ge-132 but was not detected in the sera at 12, 36, or 48 h after administration. The antiviral activity of sera from Ge-132-treated mice was inactivated by treatments with trypsin, low pH, and anti-IFN gamma antiserum. The inactivated preparations of serum IFN induced by Ge-132 did not exhibit antitumour activity when administered to tumour-bearing mice. These results suggest that antitumour activity in the sera of Ge-132-treated mice may be expressed through activities of Ge-132-induced lymphokine(s), such as IFN gamma. |
format | Text |
id | pubmed-1977232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1985 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19772322009-09-10 Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. Suzuki, F. Brutkiewicz, R. R. Pollard, R. B. Br J Cancer Research Article Sera from C57Bl/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich (allogeneic) and RL male 1 (syngeneic) ascites tumours in BALB/c mice. Sera obtained from mice 24 h after Ge-132 administration displayed the greatest antitumour effect and this was dose dependent. Sera prepared from mice 12, 36, or 48 h after Ge-132 treatment had no protective effect. Circulating interferon (IFN) was induced at 24 h after administration of Ge-132 but was not detected in the sera at 12, 36, or 48 h after administration. The antiviral activity of sera from Ge-132-treated mice was inactivated by treatments with trypsin, low pH, and anti-IFN gamma antiserum. The inactivated preparations of serum IFN induced by Ge-132 did not exhibit antitumour activity when administered to tumour-bearing mice. These results suggest that antitumour activity in the sera of Ge-132-treated mice may be expressed through activities of Ge-132-induced lymphokine(s), such as IFN gamma. Nature Publishing Group 1985-11 /pmc/articles/PMC1977232/ /pubmed/3933536 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Suzuki, F. Brutkiewicz, R. R. Pollard, R. B. Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title | Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title_full | Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title_fullStr | Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title_full_unstemmed | Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title_short | Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
title_sort | ability of sera from mice treated with ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977232/ https://www.ncbi.nlm.nih.gov/pubmed/3933536 |
work_keys_str_mv | AT suzukif abilityofserafrommicetreatedwithge132anorganicgermaniumcompoundtoinhibitexperimentalmurineascitestumours AT brutkiewiczrr abilityofserafrommicetreatedwithge132anorganicgermaniumcompoundtoinhibitexperimentalmurineascitestumours AT pollardrb abilityofserafrommicetreatedwithge132anorganicgermaniumcompoundtoinhibitexperimentalmurineascitestumours |